GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

GLP-1 receptor agonists and GLP-1 & weight loss sectors. The fund invests in growth and value stocks of companies operating across diversified market capitalization. The fund employs proprietary ...

With evidence from 85,373 participants across 11 trials, GLP-1 receptor agonists significantly reduced kidney failure risk and cardiovascular events, showing consistent benefits across diabetes ...